Navigation Links
Omnicell Announces First Quarter 2008 Results
Date:4/21/2008

et of tax when

evaluating core operating results because the tax effect related to

stock-based compensation expenses is inconsistent in amount and

frequency.

c) We concluded under Statement of Financial Accounting Standards No. 109

that a portion of our tax valuation allowance on specific deferred tax

assets was no longer required, primarily as a result of achieving

sustained profitability in certain tax jurisdictions. Therefore, we

reversed a portion of our tax valuation allowance which favorably

impacted income tax expense and net income.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results. In the future, we expect to incur expenses similar to the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

-- Omnicell's stock option and stock purchase plans are important

components of incentive compensation arrangements and compensation

related to these plans will be reflected as expenses in Omnicell's

GAAP results for the foreseeable future under SFAS No. 123R.

-- Other companies, including other companies in Omnicell's industry, may

calculate non-GAAP financial measures differently than Omnicell,

limiting their usefulness as a comparative measure.

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between the GAAP and non-GAAP financial results is set forth in the financial statements at the end of this press release. Investors are advised to carefully review and consider this information strictly as a suppleme
'/>"/>

SOURCE Omnicell, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Omnicell Schedules First Quarter 2008 Earnings Call
2. Omnicell Announces Completion of Its Common Stock Repurchase Plan
3. Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast
4. Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0
5. Omnicell Schedules Fourth Quarter Earnings Call
6. Omnicell Debuts Industrys First Total Automated Patient-Specific Management Solution
7. Omnicell Announces Agreement to Acquire Rioux Vision, Inc.
8. Omnicell to Present at Piper Jaffray 19th Annual Health Care Conference
9. Hendricks Regional Health Increases Patient Safety and Pharmacy Efficiency With Omnicell WorkflowRx 5.0
10. Omnicell Reports Strong Q3 Revenue and Profit Growth
11. Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Policy transparency key to saving worlds fisheries 8955 1Policy transparency key to saving worlds fisheries 8955 2Policy transparency key to saving worlds fisheries 8955 3Policy transparency key to saving worlds fisheries 8955 4Policy transparency key to saving worlds fisheries 8955 5Domestic Violence Expert Comments on Chris Brown Plea Deal 49697 1Domestic Violence Expert Comments on Chris Brown Plea Deal 49697 2Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 1Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 2Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 3